Alterity Therapeutics Ltd. · ASX:ATH
Alterity Therapeutics — Shareholder Meeting (December 2023)
19 slides from Alterity Therapeutics's shareholder meeting presentation, Dec 29, 2023
Slide 1: Alterity Therapeutics
Slide 2: Forward Looking Statements
» Alterity THERAPEUTICS @ Forward Looking Statements This presentation may contain some statements that may be considered “Forward-Looking Statements”, within the meaning of the US Securities Laws. Thus, any forward-looking statement relating to financial projections or other statements relating to
Slide 3: Overview of Today's Presentation
® Overview of Today’s Presentation + New Primate data with ATH434 « Update on our clinical programs + Looking forward to 2024
Slide 4: Parkinsonian Disorders: A Significant Unmet Need
® Parkinsonian Disorders: A Significant Unmet Need oflts Alterity THeRaPeuriCs PARKINSONIAN DISORDERS + Parkinsonism is a syndrome of motor symptoms that includes slowed movement, stiffness and tremor + Parkinson's disease most common cause + Major source of disability + Parkinsonian disorders inclu
Slide 5: Increased Brain Iron in Parkinson's Disease and Related Disorders
® Increased Brain Iron in Parkinson’s Disease and Related Disorders Parkinson's disease Substnti niga (1) Brace Heathy Substntaiga (oe) ° Corel ty wooo) ——20000°~=~« OOOO ‘nmol ironi/g of human brain nae tS 01 Advanced Quantitative MRI to measure brain iron MSA Control (Cay? Tt, 0, Cansen » Alterity
Slide 6: Excess Iron and Alpha-Synuclein are Strong Contributors to Disease Pathology
® Excess Iron and Alpha-Synuclein are Strong oflts Alterity Contributors to Disease Pathology a-Synuclein: protein critical for normal function of neurons + Adverse impact of excess iron + Promotes a-synuclein aggregation/clumping + Root cause of oxidative stress which damages intracellular structur
Slide 7: Approach: Address Underlying Pathology of Disease
® Approach: Address Underlying Pathology oflts Alterity of Disease Reduce a-synuclein Redistribute excess iron aggregation Rescue neuronal in the Central Nervous System and function Oxidative stress
Slide 8: ATH434: Disease Modifying Drug Candidate
ATH434: Disease Modifying Drug Candidate ATH434 redistributes excess iron and reduces a-synuclein clumping in brain + Oral agent (tablet) for ease of use * Readily absorbed, shown to reach site of action in man Potential to treat various Parkinsonian disorders Orphan Drug Designation in the US and E
Slide 9: Primate Study Validates ATH434 Clinical Approach
Primate Study Validates ATH434 Clinical Approach oflts Alterity Promising New Data THERAPEUTICS + Well established model of Parkinson’s, primate closer to humans + ATH434 treatment improved motor skills and general behavior in monkeys with experimentally induced Parkinson's disease + Favorable impac
Slide 10: Monkey Parkinson's Disease Study
® Monkey Parkinson’s Disease Study oflts Alterity THeRaPeuriCs Disease Onset Baseline ATHA34 10 malkg Motor Assessment Motor Assessment Motor Assessment Measure Brain Iron Soc: Baty, Ete ATH, Cnc Phase Sal Mace wih dete Aint kon, Heipatrsanian Macaque Faire f Pasar Does, 2023 0
Slide 11: ATH434 Improved Motor and Behavior Scores
@ ATH434 Improved Motor and Behavior Scores oflts Alterity Improvement Associated with Reduced Iron THERAPEUTICS General Motor General Behavior 8 24. . 18 * t g 4 3° 8 12 5 8 2 Lowest Iron o Levels Baseline Week 12 Smgikg 10 moka All ATH434 treated monkeys had improved Motor an Behavior scores and L
Slide 12: Accumulated Data Supports ATH434 Efficacy
® Accumulated Data Supports ATH434 Efficacy oflts Alterity Target Disease Model Brain Iron g-Synuclein ety Cees Author Parkinson's disease Mouse MPTP v v ” ee ewarce, ‘Finkelstein Parkinson's disease Mouse ASST v v oN eae. Finkelstein Parkinson's disease Mouse tau knockout v v ” ee Beauchamp MSA PLP
Slide 13: Clinical Development Progress: Multiple System Atrophy
Clinical Development Progres: Multiple System Atrophy
Slide 14: Promising Portfolio in Neurodegenerative Diseases
® Promising Portfolio in Neurodegenerative Diseases oflts Alterity PROGRAM ATH434-201 ATH434-202 bioMUSE ATH434 Drug Discovery INDICATION Multiple System Atrophy Early Stage Multiple System Atrophy Advanced Multiple System Atrophy Natural History Study Parkinson's Disease Neurodegenerative Diseases
Slide 15: Clinical Development in MSA
® Clinical Development in MSA Study ATH434-201 — Phase 2 ATH434-202 — Phase 2 » Alterity THeRaPeuriCs bioMUSE — Natural History Design Objectives Population Sample Size Treatment Primary Endpoint Secondary Endpoints Randomized, double-blind, placebo controlled Efficacy and safety of ATH434 Assess ta
Slide 16: Significant Commercial Opportunity in Multiple System Atrophy
® Significant Commer Multiple System Atrophy Substantial Unmet Need Severely det g illnesses ?, *, offo Alterity Strong Intent to Prescribe 3 Motivated by efficacy of treating with no current treatments are SS S the underlying disease and not ripe for new entrants targeting Ss just the symptoms, cli
Slide 17: Key Milestones
@ Key Milestones oflts Alterity THeRaPeuriCs Enrollment Complete ‘ATH434-201 Phase 2 Trial Data with ATH434 in Monkey Model ‘Study Complete ‘of Parkinson's ‘ATH434-201 Disease Phase 2 Trial bioMUSE Data Preliminary Data from ‘ATH434-202 Open Label Biomarker Trial Dec | Jan | Feb Apr | May | Jun | Ju
Slide 18: Poised for Progress in 2024
® Poised for Progress in 2024 oflts Alterity THERAPEUTICS + New primate data validates our clinical strategy * Achieved all clinical and corporate milestones in 2023 * ATH434: Novel drug candidate for various parkinsonian disorders + First indication: Multiple System Atrophy (MSA) + ATH434-201 (earl
Slide 19: THERAPEUTI
THERAPEUTI
Alterity Therapeutics — Shareholder Meeting (December 2023) on 6ix